“Arthritis” is not a single disease; it is a shorthand way of referring to over 100 different diseases and conditions related to joint pain. According to Hospital for Special Surgery (HSS), one in three U.S. adults suffer from some form of arthritis. Because it often goes undiagnosed, many believe this figure to be even higher.
Seeking to advance our understanding of conditions such as rheumatoid arthritis and osteoarthritis, The Tow Foundation supported the creation of the David Z. Rosensweig Genomics Research Center (the Rosensweig Center) at HSS in 2013.
Since its establishment, the Rosensweig Center has leveraged cutting edge genomics to develop personalized and effective therapies that restore mobility, enhance quality of life and improve surgical outcomes for patients with arthritis.
In 2020, the Rosensweig Center’s 15-person team of scientists, clinicians and computational biologists identified new disease-causing cell types in inflamed in joints of patients with rheumatoid arthritis and examined how these cells respond to medications. This innovative work could lead to therapies that would match patients with the most effective and safest medications based on their individual disease subtype.
